-
Press ReleaseNovartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
-
Press ReleaseNovartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
-
Story
Why advocating for your MS is so important -
Press ReleaseNovartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
-
Press ReleaseNovartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
-
Press ReleaseNew Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
-
Story
From black holes to AI driven drug discovery – collaboration wins the day -
Press ReleaseNovartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
-
Story
Beacon of Hope lights the way for a more equitable future -
Press ReleaseSandoz presents compelling investment proposition as standalone company at Capital Markets Day
-
Story
The future of medicine is here -
Press ReleaseNovartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments